Paul L. R.
- Country
- Germany
- Department
- Innere Medizin II
Research Overview
- Randomized Phase II Study of Teclistamab + Daratumumab‑Lenalidomide‑Dexamethasone (Tec‑DRd) vs Daratumumab‑Lenalidomide‑Dexamethasone (DVRd) in Transplant‑Eligible NDMM
- Phase III Randomized, Placebo-Controlled Study of Venetoclax with Induction and Consolidation Chemotherapy in Newly Diagnosed AML or MDS-EB2 Patients
- INDIE: Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
Data & Insights
Has run more than one trial at 123 of 239 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various forms of blood cancers, with particular expertise in multiple myeloma and innovative therapeutic approaches including stem cell transplantation.
- Multiple Myeloma Treatment Innovation
- Acute Myeloid Leukemia Management
- Lymphoma Therapeutics
Their work encompasses novel drug combinations and immunotherapy approaches for blood cancer treatment.
Advanced Lymphoma Care
Focuses on developing treatments for various types of lymphoma, including Hodgkin lymphoma and CNS lymphoma, with emphasis on personalized therapeutic strategies.
- CNS Lymphoma Treatment
- B-cell Non-Hodgkin Lymphoma
- Early-Stage Lymphoma Management
Specializes in developing targeted therapies and immunological approaches for lymphoma treatment.
Innovative Therapeutic Approaches
Explores cutting-edge treatment methods including targeted therapy and immunotherapy combinations for various hematologic conditions.
- Novel Drug Combinations
- Chemotherapy Optimization
- Maintenance Therapy Strategies
Implements personalized treatment approaches based on molecular and genetic markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.